What is CJC-1295 (no DAC), Mod GRF 1-29?
A modified GHRH(1-29) with four amino-acid swaps for stability; short-acting, unlike CJC-1295 with DAC.
CJC-1295 (no DAC), Mod GRF 1-29 in the library · Growth Hormone Secretagogues · Human Trials · What are peptides?
0 registered trials · 0 indexed papers · 14 human / 7 animal studies
From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.
What it is
Mod GRF 1-29 is described as GHRH(1-29) with four substitutions (positions 2, 8, 15 and 27) that resist enzyme breakdown. Sellers often call it "CJC-1295 no DAC", although the CJC-1295 (with DAC) name originally referred to the version with the drug affinity complex.
It is commonly sold alone and in blends with ipamorelin, GHRP-2 or GHRP-6.
Mechanism (as described)
- Like sermorelin, it stimulates the pituitary GHRH receptor; the substitutions are described as extending its activity from minutes to roughly half an hour.
- GHRH-type peptides and ghrelin-receptor agonists act on different receptors, which is the rationale for pairing them; GH response to GHRP-6 depends on endogenous GHRH (Pandya et al., 1998).
Evidence (as described)
- No published human trial of the modified (tetrasubstituted) peptide itself is on file. Human data on GHRH(1-29) analogs come from sermorelin and related research.
Status
Not approved anywhere; research and compounding only.
More cited research
- Activation of the GH/IGF-1 axis by CJC-1295 (with DAC), a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects (2009, human observational)
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295 (with DAC), a long-acting analog of GH-releasing hormone, in healthy ad (None, human RCT)
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295 (with DAC), a long-acting GH-releasing hormone analog (None, human trial (non-randomized))
- Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS (2016, human observational)
- Once-daily administration of CJC-1295 (with DAC), a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse (2006, animal)
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 (no DAC) a (2005, animal)
- Peptide Supplements and Their Therapeutic Applications in Sports Medicine (2026, animal)
- Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth (2009, animal)
Conditions researched
- Anti-aging & longevity
- Fat loss, obesity & body recomposition
- Low testosterone (without or alongside TRT)
- Lyme disease & chronic infections
- Multiple sclerosis
- Muscle gain, sarcopenia & building muscle after 40
Related compounds
- CJC-1295 (no DAC) (with/without DAC) + Ipamorelin
- Ipamorelin
- BPC-157
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over)
- GHK (Copper-Free)
- Parathyroid Hormone (PTH 1-84)
- ACTH (Corticotropin)
- BNP (Nesiritide)
- Carnosine
- GHK-Cu (Copper peptide)
FAQ
What is CJC-1295 (no DAC), Mod GRF 1-29?
A modified GHRH(1-29) with four amino-acid swaps for stability; short-acting, unlike CJC-1295 with DAC.
How many registered human trials study CJC-1295 (no DAC), Mod GRF 1-29?
The PeptideWhiz trial index lists 0 registered trials for CJC-1295 (no DAC), Mod GRF 1-29.
How much published research exists on CJC-1295 (no DAC), Mod GRF 1-29?
By study type, PeptideWhiz counts 14 human and 7 animal studies on CJC-1295 (no DAC), Mod GRF 1-29.
Which conditions is CJC-1295 (no DAC), Mod GRF 1-29 researched for?
Anti-aging & longevity, Fat loss, obesity & body recomposition, Low testosterone (without or alongside TRT), Lyme disease & chronic infections, Multiple sclerosis, Muscle gain, sarcopenia & building muscle after 40.
Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).